Published in Nat Med on June 20, 2010
Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev (2011) 1.93
The cell biology of polycystic kidney disease. J Cell Biol (2010) 1.58
Emerging role of autophagy in kidney function, diseases and aging. Autophagy (2012) 1.43
Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology. Nat Chem Biol (2012) 1.21
ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease. Drugs Future (2010) 1.15
Polycystic kidney disease: pathogenesis and potential therapies. Biochim Biophys Acta (2010) 1.02
The role of the cilium in normal and abnormal cell cycles: emphasis on renal cystic pathologies. Cell Mol Life Sci (2012) 0.99
CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle (2012) 0.91
A novel sphingolipid-TORC1 pathway critically promotes postembryonic development in Caenorhabditis elegans. Elife (2013) 0.91
Drug discovery for polycystic kidney disease. Acta Pharmacol Sin (2011) 0.90
Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nat Rev Nephrol (2015) 0.89
Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells. Am J Physiol Renal Physiol (2015) 0.89
Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model. PLoS One (2013) 0.88
Advances in our understanding of the pathogenesis of HIV-1 associated nephropathy in children. Future Virol (2011) 0.85
Accumulation of long-chain glycosphingolipids during aging is prevented by caloric restriction. PLoS One (2011) 0.85
An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease. Nephrol Dial Transplant (2014) 0.85
New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol (2013) 0.85
A world of sphingolipids and glycolipids in the brain--novel functions of simple lipids modified with glucose. Proc Jpn Acad Ser B Phys Biol Sci (2012) 0.84
MALDI imaging MS reveals candidate lipid markers of polycystic kidney disease. J Lipid Res (2013) 0.83
The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans Am Clin Climatol Assoc (2013) 0.82
Adamantyl glycosphingolipids provide a new approach to the selective regulation of cellular glycosphingolipid metabolism. J Biol Chem (2011) 0.82
Loss of GM3 synthase gene, but not sphingosine kinase 1, is protective against murine nephronophthisis-related polycystic kidney disease. Hum Mol Genet (2012) 0.81
Simplifying complexity: genetically resculpting glycosphingolipid synthesis pathways in mice to reveal function. Glycoconj J (2014) 0.80
Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars. ACS Med Chem Lett (2010) 0.80
An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. Hum Mol Genet (2014) 0.79
Age-dependent changes in the sphingolipid composition of mouse CD4+ T cell membranes and immune synapses implicate glucosylceramides in age-related T cell dysfunction. PLoS One (2012) 0.78
AMP-activated Protein Kinase Suppresses Biosynthesis of Glucosylceramide by Reducing Intracellular Sugar Nucleotides. J Biol Chem (2015) 0.77
Dysregulated sphingolipid metabolism in endometriosis. J Clin Endocrinol Metab (2014) 0.77
Neurofibromatosis-like phenotype in Drosophila caused by lack of glucosylceramide extension. Proc Natl Acad Sci U S A (2012) 0.77
Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease. J Biol Chem (2014) 0.77
The consequences of genetic and pharmacologic reduction in sphingolipid synthesis. J Inherit Metab Dis (2014) 0.76
Synthesis of a novel photoactivatable glucosylceramide cross-linker. J Lipid Res (2016) 0.75
Telling kidneys to cease and decyst. Nat Med (2010) 0.75
Targeting Glycosphingolipid Metabolism to Treat Kidney Disease. Nephron (2016) 0.75
Scientific literature on monosialoganglioside in the Science Citation Index-Expanded: A bibliometric analysis of articles from 1942 to 2011 by each decade. Neural Regen Res (2012) 0.75
Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis. Hum Mol Genet (2016) 0.75
Genetic diseases: new tricks for known drugs. Nat Rev Drug Discov (2010) 0.75
Tubular cell phenotype in HIV-associated nephropathy: role of phospholipid lysophosphatidic acid. Exp Mol Pathol (2015) 0.75
Differences in the timing and magnitude of Pkd1 gene deletion determine the severity of polycystic kidney disease in an orthologous mouse model of ADPKD. Physiol Rep (2016) 0.75
High-resolution genetic localization of a modifying locus affecting disease severity in the juvenile cystic kidneys (jck) mouse model of polycystic kidney disease. Mamm Genome (2016) 0.75
A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem (1957) 173.99
Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat Genet (2005) 6.67
Autosomal dominant polycystic kidney disease. N Engl J Med (1993) 5.64
Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature (1996) 5.48
Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med (2003) 3.78
Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int (2009) 3.66
Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol (2002) 3.52
Rapid generation of inducible mouse mutants. Nucleic Acids Res (2003) 2.77
Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol (2004) 2.69
Nephronophthisis: disease mechanisms of a ciliopathy. J Am Soc Nephrol (2008) 2.66
Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci U S A (2003) 2.56
NEK8 mutations affect ciliary and centrosomal localization and may cause nephronophthisis. J Am Soc Nephrol (2008) 2.39
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood (2010) 2.38
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature (2006) 2.29
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem (2004) 2.26
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant (2005) 2.09
Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem (2001) 2.04
Cilia and the cell cycle? J Cell Biol (2005) 1.94
The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci (2007) 1.89
Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes (2007) 1.82
Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol (2006) 1.78
Improved inhibitors of glucosylceramide synthase. J Biol Chem (1999) 1.72
Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol (2010) 1.70
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab (2007) 1.61
Improved inhibitors of glucosylceramide synthase. J Biochem (1992) 1.40
Cell cycle arrest induced by an inhibitor of glucosylceramide synthase. Correlation with cyclin-dependent kinases. J Biol Chem (1995) 1.39
GM1 and GM3 gangliosides highlight distinct lipid microdomains within the apical domain of epithelial cells. FEBS Lett (2007) 1.33
A hereditary model of slowly progressive polycystic kidney disease in the mouse. J Am Soc Nephrol (1991) 1.16
Modulation of renal epithelial cell growth by glucosylceramide. Association with protein kinase C, sphingosine, and diacylglycerol. J Biol Chem (1991) 1.13
Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures. Am J Physiol Renal Physiol (2007) 1.03
Abnormalities of glycosphingolipid, sulfatide, and ceramide in the polycystic (cpk/cpk) mouse. J Lipid Res (1994) 0.99
Integration of glycosphingolipid metabolism and cell-fate decisions in cancer and stem cells: review and hypothesis. Glycoconj J (2004) 0.97
Ganglioside GM3 inhibition of EGF receptor mediated signal transduction. Glycobiology (1996) 0.96
Insulin-like growth factor-1 receptor signaling in 3T3-L1 adipocyte differentiation requires lipid rafts but not caveolae. Cell Death Differ (2004) 0.93
Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease. Nephrology (Carlton) (2007) 0.93
Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. J Lipid Res (1996) 0.90
Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD. Nephrol Dial Transplant (2010) 0.89
Potential pharmacological interventions in polycystic kidney disease. Drugs (2007) 0.84
The Amber biomolecular simulation programs. J Comput Chem (2005) 28.84
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med (2010) 5.92
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol (2005) 5.27
The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Dev Cell (2008) 4.90
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2006) 4.87
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med (2008) 4.04
Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release (2006) 3.85
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev (2003) 3.53
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol (2009) 2.70
Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell (2012) 2.54
Hedgehog-regulated Costal2-kinase complexes control phosphorylation and proteolytic processing of Cubitus interruptus. Dev Cell (2005) 2.50
Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation (2002) 2.49
Hedgehog signalling activity of Smoothened requires phosphorylation by protein kinase A and casein kinase I. Nature (2004) 2.39
Genome sequencing and comparative transcriptomics of the model entomopathogenic fungi Metarhizium anisopliae and M. acridum. PLoS Genet (2011) 2.35
Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature (2006) 2.29
Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus. Nature (2002) 2.26
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer (2010) 2.19
Hippo signaling regulates Drosophila intestine stem cell proliferation through multiple pathways. Proc Natl Acad Sci U S A (2010) 2.16
A hedgehog-induced BTB protein modulates hedgehog signaling by degrading Ci/Gli transcription factor. Dev Cell (2006) 2.13
Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology (Williston Park) (2009) 2.12
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med (2002) 2.12
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. N Engl J Med (2015) 2.10
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther (2008) 2.07
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther (2011) 2.04
Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. J Clin Invest (2004) 2.00
Controlling the Kondo effect of an adsorbed magnetic ion through its chemical bonding. Science (2005) 1.98
IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol (2007) 1.96
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol (2010) 1.86
Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes (2007) 1.82
Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release (2007) 1.79
Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol (2006) 1.78
Bradykinin-induced microglial migration mediated by B1-bradykinin receptors depends on Ca2+ influx via reverse-mode activity of the Na+/Ca2+ exchanger. J Neurosci (2007) 1.74
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol (2006) 1.69
Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther (2008) 1.65
Injection of AAV2-BMP2 and AAV2-TIMP1 into the nucleus pulposus slows the course of intervertebral disc degeneration in an in vivo rabbit model. Spine J (2011) 1.63
A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol (2010) 1.63
Phosphorylation by double-time/CKIepsilon and CKIalpha targets cubitus interruptus for Slimb/beta-TRCP-mediated proteolytic processing. Dev Cell (2005) 1.62
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res (2003) 1.61
Microporous and photoluminescent chalcogenide zeolite analogs. Science (2002) 1.61
Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses. J Virol (2009) 1.61
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab (2007) 1.61
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood (2013) 1.59
Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther (2002) 1.56
Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther (2010) 1.56
Monoamine oxidase A gene polymorphism predicts adolescent outcome of attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2007) 1.51
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol (2010) 1.51
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res (2006) 1.50
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood (2013) 1.48
Multiple Ser/Thr-rich degrons mediate the degradation of Ci/Gli by the Cul3-HIB/SPOP E3 ubiquitin ligase. Proc Natl Acad Sci U S A (2009) 1.47
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res (2013) 1.47
Fine-mapping gene-by-diet interactions on chromosome 13 in a LG/J x SM/J murine model of obesity. Diabetes (2005) 1.47
Regulation of TopBP1 oligomerization by Akt/PKB for cell survival. EMBO J (2006) 1.45
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol (2009) 1.44
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol (2004) 1.43
Atomic structure, energetics, and dynamics of topological solitons in indium chains on Si(111) surfaces. Phys Rev Lett (2011) 1.42
Retracted Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis. J Ovarian Res (2013) 1.42
Structural Survey of Zinc Containing Proteins and the Development of the Zinc AMBER Force Field (ZAFF). J Chem Theory Comput (2010) 1.37
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int (2011) 1.37
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer (2006) 1.36
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol (2005) 1.35
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol (2009) 1.34
Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res (2005) 1.32
Formal Estimation of Errors in Computed Absolute Interaction Energies of Protein-ligand Complexes. J Chem Theory Comput (2011) 1.32
Genomic imprinting effects on adult body composition in mice. Proc Natl Acad Sci U S A (2008) 1.31
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant (2008) 1.30
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. J Exp Med (2005) 1.30
SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids. PLoS One (2012) 1.29
Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. Biomaterials (2009) 1.29
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood (2007) 1.29
A method of calculating the second dimension retention index in comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry. J Chromatogr A (2011) 1.28
Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation (2005) 1.28
Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer. Mol Cell Biol (2009) 1.28
Identification of quantitative trait loci affecting murine long bone length in a two-generation intercross of LG/J and SM/J Mice. J Bone Miner Res (2008) 1.26
Prediction of protein-protein interactions from amino acid sequences with ensemble extreme learning machines and principal component analysis. BMC Bioinformatics (2013) 1.26
Functional analysis of PKD1 transgenic lines reveals a direct role for polycystin-1 in mediating cell-cell adhesion. J Am Soc Nephrol (2003) 1.26
Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2004) 1.25
The immediate environment during postnatal development has long-term impact on gut community structure in pigs. ISME J (2008) 1.25
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood (2011) 1.25
Lysosomal phospholipase A2 and phospholipidosis. Mol Cell Biol (2006) 1.23
An optimal peak alignment for comprehensive two-dimensional gas chromatography mass spectrometry using mixture similarity measure. Bioinformatics (2011) 1.22
The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res (2004) 1.22
Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab (2008) 1.21
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol (2007) 1.21
Transforming growth factor-beta, 20-HETE interaction, and glomerular injury in Dahl salt-sensitive rats. Hypertension (2005) 1.20
Genetic architecture of adiposity and organ weight using combined generation QTL analysis. Obesity (Silver Spring) (2008) 1.20